

We are MeOmics

Our Neural Biomarker Platform Will
Transform Mental Health Drug Development

 Alasdair Pettigrew

 +44 7711 850102

 alasdair@meomics.tech

WWW.MEOMICS.TECH



— The Time is Right for the **MeOmics Vision**

MeOmics has built the first neuronal cell panel of schizophrenia...

Making unique data available for AI-based med-tech companies to use, presenting early revenue opportunities for MeOmics

MeOmics is now building the world's first high throughput drug screening platform for mental health conditions...

Meaning drug developers will be able to reduce the cost and risk of clinical trials, presenting significant revenue opportunities for MeOmics

— Global Challenge of **Mental Health**



Mental Health
Illnesses are:
**Half of Top 10
Conditions**





Global Mental
Illness Costs:
**Hundreds of
\$BILLIONS**



High Drug Dev.
Failure Rate:
**Only 1 in 20
Succeed**

— The MeOmics **Value Proposition**

**A Neuronal Biomarker
Platform from clinical patients**




— The MeOmics Platform

Population




“population on a plate”




+ Pharmacology




“drug” screen



= Prediction



AI/ML analysis to identify patient clusters and match drug to patient




— MeOmics Key Milestones Achieved

Population


- ✓ *Generate 150 iPSC lines from 50 patient donors*
- ✓ *Stored as MEA-ready master stocks*
- ✓ *Conduct highly parallel MEA assays*




+ Pharmacology




= Prediction




*AI/ML analysis **commencing** to identify patient clusters and match drug to patient*



MeOmics Has Built an **Assay** to **Distinguish** **Schizophrenia Patients** from **Controls**




— Highly Scalable **Business Models**





Revenue Growth Projections

MeOmics Revenue & Cost Plan



Competitive Landscape is Evolving



Global Research &
Press Interest e.g. :

The Economist



Early-Stage
Competitors are
Emerging e.g. :


Herophilus



Established Firms
May Pivot e.g. :

**Fujifilm Cellular
Dynamics**

— Significant Business **Validation & Traction**



— Recent **Value Inflection Points** for MeOmics

Recent Scientific & business Achievements (as of mid-2024)



Pipeline from patients to iPSC

- ✓ Recruitment of 50 Schizophrenia Patients
- ✓ Generation of 300 iPSC lines (6 from each of the 50 donors)



Assay-ready cells

- ✓ Generation of iPSC master stocks from all 150 clones
- ✓ Stored as Neural Progenitor Cells, ready for cell assays



Differential Signals Detected and Patent(s) Being Filed

- ✓ Demonstrated electrophysiological signals differentiate patient & non-patient cells
- ✓ Indications of patient stratification differences - signal data AI/ML analysis commencing



Parallelisation of MEA assays

- ✓ Ongoing assay of 28 patients and control iPSC-derived neurons (multi-well format)
- ✓ Testing four novel compounds has shown “normalisation” of schizophrenia signal



Engagement with Initial Customers

- ✓ First commercial proposals submitted to rare disease patient groups
- ✓ Ongoing screening platform discussions with interested drug development companies

— MeOmics - Significant ESG Impact

MeOmics are committed
to protecting the
environment



Enabling the reduction
in animal testing in
drug development

MeOmics are committed
to good governance



Actively adopting best
practice governance
processes and policies


MeOmics will deliver
significant social
impact



Creating high-value
jobs and investment in
South Wales

The most **profound** MeOmics
social impact will be the global **transformation** of **mental illnesses**

— How MeOmics Will **Use** this **Pre-Seed Funding**



MeOmics
is now open to a

£1m Pre-Seed Fundraise

—

SEIS/EIS Advanced
Assurance secured
from HMRC

WITH THIS MONEY WE WILL:

- + **Gather more patient samples** – targeting around 150 in total, gathering highly valuable data
- + **Accelerate** our **process throughput** with robotics and automation
- + Recruit **data analysts** to ramp up **AI data merging, ML** and **population modelling**
- + **Secure** early **revenues** from medical AI/ML companies
- + Commence preparations to establish our **lab in the Cardiff area**

This capital plus grant funding will provide a runway to the Seed fundraise of £3m in early 2026

Allowing the recruitment of a commercial team to find customers and grow revenues, carrying MeOmics past breakeven and into positive EBITDA

— Introducing Team MeOmics

MeOmics Leadership Team



Alasdair Pettigrew
CEO

Technology
Commercialisation Expert

[Biography Link](#)



Dr Lucy Sykes
CSO

Expert in Cell &
Molecular Biology

[Biography Link](#)

MeOmics Technical Team



Alicia Campbell
Head of Lab

Upscaling stem cells and
Process Expert

[Biography Link](#)



Joshua Bugg
Data AI/ML Analyst

Expert in Biological &
Neurotechnology Data Science

[Biography Link](#)

MeOmics Scientific Advisory Board

Professor
Adrian Harwood

Co-Founder / Inventor

[Biography Link](#)

Professor
Jeremy Hall

Co-Founder / Inventor

[Biography Link](#)

Marcus Harrison

BioTech Expert

[Biography Link](#)

Professor
James Walters

Genomics Expert


[Biography Link](#)

Accounting & Finance

Rob Griffiths

CFO / Accountant

[Biography Link](#)



MeOmics plan to develop a unique platform for neural biomarker discovery that will transform drug development for mental illness

 Alasdair Pettigrew

 +44 7711 850102

 alasdair@meomics.tech

WWW.MEOMICS.TECH